• The original Bee Synch methodology

  2022-01-03

  

  The original Bee Synch methodology (now termed Bee Synch I) utilizes a 5-day CIDR, GnRH (GnRH-1) and PGF on day 0, double dose of PGF on day 5, and FTAI with GnRH (GnRH-2) at 66 h after CIDR removal. Cruppe et al. (2014) reported that the inclusion of GnRH on day 0 does not contribute appreciably to

• However no reviews was focused on

  2022-01-03

  

  However, no reviews was focused on all the glutamate heteroreceptor complexes and how to understand why some were formed and not others in the glutamate synapses and their extrasynaptic regions. These receptor complexes are present on the glutamate nerve terminals and the dendritic spines on which t

• As a part of our

  2022-01-03

  

  As a part of our continuing efforts towards discovery of new class of compounds against different therapeutic areas and based on the literature reports, we designed a dual pharmacophore which possess a long aliphatic chain of free fatty acids and a phenyl propanoid part of known GPR40 agonists. Here

• FFAs concentration response curves for increasing intracellu

  2022-01-03

  

  FFAs concentration–response curves for increasing intracellular calcium and receptor phosphorylation showed a difference of ≈1 order of magnitude indicating a relatively large receptor reserve, which is expected for a transfected model, and that high receptor occupancy is necessary to induce recepto

• Structurally the termini of FGF are

  2022-01-03

  

  Structurally, the termini of FGF21 are critical for effective signaling. Progressive amino telomerase inhibitor truncation at either end of the protein sequentially impairs FGF21 bioactivity, but via different mechanisms. Shortening at the N-terminus weakens its ability to activate the FGFR/KLB-com

• Plasmid construction and site directed mutagenesis of

  2022-01-03

  

  Plasmid construction and site-directed mutagenesis of M. luteus B-P 26 UPS. For the expression of N-terminus His6-tagged M. luteus B-P 26 UPS, the expression plasmid pMluUEX [7] was cleaved with the restriction enzymes NdeI/BamHI. The gene fragment was inserted into an NdeI/BamHI-treated pET-15b to

• Hyperhomocysteinemia HHcy is a clinical condition characteri

  2022-01-03

  

  Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino lysophosphatidic acid australia formed during the intracellular conversion of methionine to cysteine.

• One of the possibilities of HO targeting

  2022-01-03

  

  One of the possibilities of HO-1 targeting is gene therapy. So far, the majority of preclinical studies have focused on recombinant adeno-associated viral (rAAV) vectors as DNA carriers. They not only provide stable, long-term transgene expression in non-dividing flavin adenine dinucleotide australi

7883 records 526/526 page Previous First page 上5页 526